Drug intelligence / Profile preview

Norditropine SimpleXx

Development stage
Approved
Lead developer
Novo Nordisk
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

Norditropine SimpleXx is a liquid formulation of somatropin, a recombinant human growth hormone (rhGH), designed for use in specialized delivery pens. Developed and manufactured by Novo Nordisk, it contains a 191-amino acid polypeptide chain that is identical to the growth hormone naturally produced by the human pituitary gland. Somatropin acts as a potent agonist at the Growth Hormone Receptor (GHR), initiating signaling cascades (primarily the JAK2/STAT5 pathway) that stimulate the production of Insulin-like Growth Factor 1 (IGF-1). This process promotes longitudinal bone growth, protein synthesis, and metabolic regulation. It is indicated for children with growth failure due to growth hormone deficiency, Turner syndrome, Noonan syndrome, chronic renal insufficiency, and for children born small for gestational age (SGA) who fail to show catch-up growth. It is also utilized for replacement therapy in adults with confirmed growth hormone deficiency.

Brand names
Norditropine SimpleXxNorditropin
Other names
somatropinrecombinant human growth hormonerhGH
02

Targets

GHR (Growth hormone receptor)

Beyond the preview

Go deeper on Norditropine SimpleXx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Norditropine SimpleXx.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call